
Sharon M Castellino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1613229/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nature Genetics, 2014, 46, 438-443.	21.4	383
2	Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood, 2011, 117, 1806-1816.	1.4	307
3	Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report. Biology of Blood and Marrow Transplantation, 2016, 22, 782-795.	2.0	155
4	Developing Interventions for Cancer-Related Cognitive Dysfunction in Childhood Cancer Survivors. Journal of the National Cancer Institute, 2014, 106, dju186-dju186.	6.3	118
5	Age-Dependent Changes in Health Status in the Childhood Cancer Survivor Cohort. Journal of Clinical Oncology, 2015, 33, 479-491.	1.6	98
6	Validity and Reliability of the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events. Journal of the National Cancer Institute, 2020, 112, 1143-1152.	6.3	59
7	Decline in Physical Activity Level in the Childhood Cancer Survivor Study Cohort. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1619-1627.	2.5	46
8	Effect of Race on the Outcome of Pediatric Patients With Hodgkin's Lymphoma. Journal of Clinical Oncology, 2008, 26, 1282-1288.	1.6	44
9	Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group. Cancer, 2018, 124, 3210-3219.	4.1	39
10	Survival by Race and Ethnicity in Pediatric and Adolescent Patients With Hodgkin Lymphoma: A Children's Oncology Group Study. Journal of Clinical Oncology, 2019, 37, 3009-3017.	1.6	34
11	Pediatric genitourinary tumors. Current Opinion in Oncology, 2009, 21, 278-283.	2.4	24
12	Association of <i>GSTM1</i> null variant with anthracyclineâ€related cardiomyopathy after childhood cancer—A Children's Oncology Group ALTE03N1 report. Cancer, 2020, 126, 4051-4058.	4.1	23
13	Suboptimal uptake of human papillomavirus (HPV) vaccine in survivors of childhood and adolescent and young adult (AYA) cancer. Journal of Cancer Survivorship, 2019, 13, 730-738.	2.9	22
14	Earlyâ€stage Hodgkin lymphoma in the modern era: simulation modelling to delineate longâ€ŧerm patient outcomes. British Journal of Haematology, 2018, 182, 212-221.	2.5	17
15	Pediatric genitourinary tumors. Current Opinion in Oncology, 2007, 19, 248-253.	2.4	16
16	Cost, Value, and Financial Hardship in Cancer Care: Implications for Pediatric Oncology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 850-860.	3.8	16
17	Association of Medicaid Expansion With Cancer Stage and Disparities in Newly Diagnosed Young Adults. Journal of the National Cancer Institute, 2021, 113, 1723-1732.	6.3	16
18	Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group. Cancer Treatment Reviews, 2021, 100, 102296.	7.7	16

#	Article	IF	CITATIONS
19	Closing the survivorship gap in children and adolescents with Hodgkin lymphoma. British Journal of Haematology, 2019, 187, 573-587.	2.5	15
20	Growth disturbances in children and adolescents receiving longâ€ŧerm tyrosine kinase inhibitor therapy for Chronic Myeloid Leukaemia or Philadelphia Chromosomeâ€positive Acute Lymphoblastic Leukaemia. British Journal of Haematology, 2019, 185, 795-799.	2.5	9
21	Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials. Lancet Haematology,the, 2022, 9, e49-e57.	4.6	9
22	Dealing with a critical national shortage—Approaches to triaging immune globulin supply in pediatric hematology and oncology. Pediatric Blood and Cancer, 2020, 67, e28260.	1.5	8
23	Integration of Pediatric Hodgkin Lymphoma Treatment and Late Effects Guidelines: Seeing the Forest Beyond the Trees. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 755-764.	4.9	7
24	Quantifying the difference in risk of adverse events by induction treatment regimen in pediatric acute lymphoblastic leukemia. Leukemia and Lymphoma, 2021, 62, 899-908.	1.3	6
25	Renal and Hepatic Health After Childhood Cancer. Pediatric Clinics of North America, 2020, 67, 1203-1217.	1.8	5
26	Narrowing Insurance Disparities Among Children and Adolescents With Cancer Following the Affordable Care Act. JNCI Cancer Spectrum, 2022, 6, .	2.9	5
27	Evaluating Disparities in Proton Radiation Therapy Use in AHOD1331, a Contemporary Children's Oncology Group Trial for Advanced-Stage Hodgkin Lymphoma. International Journal of Particle Therapy, 2022, 8, 55-57.	1.8	4
28	Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias. BMC Cancer, 2021, 21, 474.	2.6	3
29	Survival by age in children and adolescents with Hodgkin lymphoma: A pooled analysis of Children's Oncology Group (COG) trials Journal of Clinical Oncology, 2018, 36, 7543-7543.	1.6	3
30	Racial Disparities in Children, Adolescents, and Young Adults with Hodgkin Lymphoma Enrolled in the New York State Medicaid Program. Journal of Adolescent and Young Adult Oncology, 2021, , .	1.3	3
31	A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes. Leukemia Research, 2020, 96, 106421.	0.8	2
32	Health-Related Quality of Life (HRQL) Trajectories during Treatment for Advanced Stage Pediatric Hodgkin Lymphoma (HL). Blood, 2018, 132, 3587-3587.	1.4	2
33	119 Improving the Quality of Bone Marrow Biopsy in a Pediatric Hospital. American Journal of Clinical Pathology, 2018, 149, S51-S51.	0.7	1
34	Impact of fluid overload and infection on respiratory adverse event development during induction therapy for childhood acute myeloid leukemia. Pediatric Blood and Cancer, 2019, 66, e27975.	1.5	1
35	Approach and Feasibility of Patient-Reported Outcomes (PROs) in a Phase III Clinical Trial for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Children and Adolescents. Blood, 2016, 128, 3583-3583.	1.4	1
36	Productivity Loss Among Parent Caregivers Is Associated with Poor Health-Related Quality of Life (HRQL) at the Intial Diagnosis of Pediatric Advanced Stage Hodgkin Lymphoma (HL). Blood, 2018, 132, 975-975.	1.4	1

#	Article	IF	CITATIONS
37	Analysis of Single Cell Transcriptomics in Paired Pediatric T-ALL Samples Collected at Diagnosis and Following End of Induction Therapy Reveals an MRD-Associated Stem Cell Signature. Blood, 2021, 138, 1311-1311.	1.4	1
38	Characterization of T-ALL-Specific Heterogenous Blast Populations Using High Resolution Single Cell Profiling. Blood, 2020, 136, 11-12.	1.4	1
39	Moving Beyond Patient-Level Drivers of Racial/Ethnic Disparities in Childhood Cancer. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1154-1158.	2.5	1
40	Comment on: Value of flow cytometric analysis of peripheral blood samples in children diagnosed with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2018, 65, e26845.	1.5	0
41	<i>Single Cell RNA Sequencing Driven Characterization of Rare B/Myeloid and T/Myeloid Mixed Phenotype Acute Leukemia</i> . Blood, 2021, 138, 3455-3455.	1.4	0
42	Frequency and Timing of Palliative Opportunities in Pediatric Patients with Hematologic Malignancies. Blood, 2020, 136, 25-25.	1.4	0
43	Evaluation of Activation of a NCI National Clinical Trials Network (NCTN) Study S1826 for Hodgkin	1.4	0